Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.68 |
| ▸ | CTSB | P07858 | 1/20 | 0.68 |
| ▸ | CTSK | P43235 | 1/20 | 0.68 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | DPP4 | P27487 | 6/20 | 0.57 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | TGM2 | P21980 | 3/20 | 0.53 |
| ▸ | F13A1 | P00488 | 2/20 | 0.53 |
| ▸ | TGM1 | P22735 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3667335 | 1.00 | CTSL (0.68) | CTSLCTSBCTSKHSD11B1ALDH1A1 | |
| SCHEMBL3003867 | 1.00 | CTSL (0.68) | CTSLCTSBCTSKHSD11B1ALDH1A1 | |
| SCHEMBL3489847 | 0.92 | CTSL (0.62) | CTSLCTSBCTSKHSD11B1ALDH1A1 | |
| SCHEMBL1870932 | 0.92 | ALDH1A1 (0.67) | CTSLCTSBCTSKHSD11B1ALDH1A1 | |
| SCHEMBL22469441 | 0.92 | HSD11B1 (0.59) | CTSLCTSBCTSKHSD11B1ALDH1A1 | |
| SCHEMBL22469852 | 0.92 | HSD11B1 (0.59) | CTSLCTSBCTSKHSD11B1ALDH1A1 | |
| SCHEMBL22469095 | 0.92 | HSD11B1 (0.59) | CTSLCTSBCTSKHSD11B1ALDH1A1 | |
| SCHEMBL3487634 | 0.91 | DPP4 (0.61) | CTSLCTSBCTSKHSD11B1ALDH1A1 | |
| SCHEMBL22829637 | 0.91 | DPP4 (0.61) | CTSLCTSBCTSKHSD11B1ALDH1A1 | |
| SCHEMBL13161203 | 0.91 | HSD11B1 (0.72) | CTSLCTSBCTSKHSD11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10064839-B2 | Methods of treating liver diseases | ZAFGEN, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| US-20180002307-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2018-01-04 | — | — | US | disclosed |
| US-20170326099-A1 | METHODS OF TREATING LIVER DISEASES | ZAFGEN, INC. | 2017-11-16 | — | — | US | disclosed |
| US-9617237-B2 | Partially saturated tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9561209-B2 | Methods of treating liver diseases | ZAFGEN, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20170001973-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2017-01-05 | — | — | US | disclosed |
| CN-103764641-B | The tricyclic compound of fractional saturation and preparation and application thereof | 扎夫根股份有限公司 | 2016-10-26 | — | — | CN | disclosed |
| EP-2705030-B1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2016-07-27 | — | — | EP | disclosed |
| US-9290472-B2 | Partially saturated tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20160058731-A1 | METHODS OF TREATING LIVER DISEASES | ZAFGEN, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| WO-2012154676-A9 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC. (US) | 2014-03-27 | — | — | WO | disclosed |
| US-20140088078-A1 | Partially Saturated Tricyclic Compounds and Methods of Making and Using Same | ZAFGEN, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| EP-2705030-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC. (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012154676-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001973-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | DNPEP, CES2, AADAC | CTSL 85/4885CTSB 143/4885CTSK 332/4885 |
| US-20170326099-A1 | METHODS OF TREATING LIVER DISEASES | ENPEP, GOT2, METAP2 | CTSL 161/4885CTSB 186/4885CTSK 351/4885 |
| US-10064839-B2 | Methods of treating liver diseases | ENPEP, GOT2, METAP2 | CTSL 161/4885CTSB 186/4885CTSK 351/4885 |
| US-20160058731-A1 | METHODS OF TREATING LIVER DISEASES | ENPEP, GOT2, METAP2 | CTSL 161/4885CTSB 186/4885CTSK 351/4885 |
| US-20180002307-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | DNPEP, CES2, AADAC | CTSL 85/4885CTSB 143/4885CTSK 332/4885 |
| US-20140088078-A1 | Partially Saturated Tricyclic Compounds and Methods of Making and Using Same | DNPEP, CES2, AADAC | CTSL 85/4885CTSB 143/4885CTSK 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.